| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC | President and CEO, Director | Stock Option (right to buy) | 400K | $576K | $1.44 | Aug 15, 2022 | Direct |
| Clovis Oncology, Inc. | Director | Stock Option (right to buy) | 42.2K | Jun 10, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| BLCM | BELLICUM PHARMACEUTICALS, INC | Aug 15, 2022 | 1 | $576K | 4 | Aug 16, 2022 | President and CEO, Director |
| BLCM | BELLICUM PHARMACEUTICALS, INC | Aug 16, 2021 | 1 | $0 | 4/A | Aug 18, 2021 | President and CEO, Director |
| CLVS | Clovis Oncology, Inc. | Jun 10, 2021 | 1 | $0 | 4 | Jun 11, 2021 | Director |